However, in acute myeloid leukemia (AML) patients with activating mutations in FMS‐like tyrosine kinase 3 (FLT3), USP10 deubiquitinates and stabilizes FLT3 by removing the proteolytic polyubiquitin chains and preventing FLT3 degradation, to aggravate tumor progress (Weisberg et al., 2017). This evidence concerns the gene FLT3 and neoplasm.